Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Drake

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1997
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivoB J Votta, M A Levy, A Badger, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1997
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivoB J Votta, M A Levy, A Badger, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis modelW H Miller, W E Bondinell, R D Cousins, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Pageof 15